TechonoDerma is an innovation-oriented R&D biotech focusing on the development of novel small molecule drugs for dermatological conditions. Located in Jiaxing Xiuzhou Biopharmaceutical National Park, TechnoDerma has been designated as a leading enterprise by the Jiaxing Municipal Government of Zhejiang Province.
The company's current R&D pipeline includes candidate drugs for hair loss, atopic dermatitis, psoriasis, and systemic lupus erythematosus (SLE). TechnoDerma's first and the most advanced research and development program is the first-in-class small molecule drug candidate TDM-105795 for the treatment of androgenetic alopecia（AGA), which has been granted global intellectual property rights. In addition, TechnoDerma has several ongoing programs for the treatment of psoriasis and atopic dermatitis, which have entered the CMC and preclinical stage. The atopic dermatitis program is expected to file IND and phase I clinical trials beginning 2022, while the psoriasis drug candidate is anticipated to file IND by end of 2022. TechnoDerma will position its highly selective non-receptor tyrosine kinase Tyk2 inhibitor as a drug candidate for the systemic treatment of SLE and other autoimmune-related skin diseases. The company will continue to expand the research and development effort for skin indications and strengthen its R&D team.